Literature DB >> 25387893

Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC.

Scot D Liu1, Cecile Chalouni2, Judy C Young3, Teemu T Junttila4, Mark X Sliwkowski5, John B Lowe2.   

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) is a key mechanism by which therapeutic antibodies mediate their antitumor effects. The absence of fucose on the heavy chain of the antibody increases the affinity between the antibody and FcγRIIIa, which results in increased in vitro and in vivo ADCC compared with the fucosylated form. However, the cellular and molecular mechanisms responsible for increased ADCC are unknown. Through a series of biochemical and cellular studies, we find that human natural killer (NK) cells stimulated with afucosylated antibody exhibit enhanced activation of proximal FcγRIIIa signaling and downstream pathways, as well as enhanced cytoskeletal rearrangement and degranulation, relative to stimulation with fucosylated antibody. Furthermore, analysis of the interaction between human NK cells and targets using a high-throughput microscope-based antibody-dependent cytotoxicity assay shows that afucosylated antibodies increase the number of NK cells capable of killing multiple targets and the rate with which targets are killed. We conclude that the increase in affinity between afucosylated antibodies and FcγRIIIa enhances activation of signaling molecules, promoting cytoskeletal rearrangement and degranulation, which, in turn, potentiates the cytotoxic characteristics of NK cells to increase efficiency of ADCC. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25387893     DOI: 10.1158/2326-6066.CIR-14-0125

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  25 in total

1.  Implications of understanding the signaling, cellular, and cytotoxic mechanisms afforded by afucosylated antibodies.

Authors:  Scot D Liu; John B Lowe
Journal:  Oncoimmunology       Date:  2015-05-08       Impact factor: 8.110

Review 2.  Diversification of IgG effector functions.

Authors:  Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Int Immunol       Date:  2017-07-01       Impact factor: 4.823

Review 3.  Signaling by Antibodies: Recent Progress.

Authors:  Stylianos Bournazos; Taia T Wang; Rony Dahan; Jad Maamary; Jeffrey V Ravetch
Journal:  Annu Rev Immunol       Date:  2017-04-26       Impact factor: 28.527

Review 4.  Functional diversification of IgGs through Fc glycosylation.

Authors:  Taia T Wang; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

5.  A Robust and Versatile Automated Glycoanalytical Technology for Serum Antibodies and Acute Phase Proteins: Ovarian Cancer Case Study.

Authors:  Róisín O'Flaherty; Mohankumar Muniyappa; Ian Walsh; Henning Stöckmann; Mark Hilliard; Richard Hutson; Radka Saldova; Pauline M Rudd
Journal:  Mol Cell Proteomics       Date:  2019-08-30       Impact factor: 5.911

Review 6.  Fcγ Receptor Function and the Design of Vaccination Strategies.

Authors:  Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Immunity       Date:  2017-08-15       Impact factor: 31.745

Review 7.  Targeting CD20: teaching an old dog new tricks.

Authors:  Jeff P Sharman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering.

Authors:  Hong Xu; Hongfen Guo; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2016-05-16       Impact factor: 11.151

Review 9.  Glycosylation in cancer: mechanisms and clinical implications.

Authors:  Salomé S Pinho; Celso A Reis
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

10.  Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.

Authors:  Rabih Said; Apostolia M Tsimberidou
Journal:  Expert Opin Biol Ther       Date:  2017-09-11       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.